Role of STAT3 in Cancer Metastasis and Translational Advances

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Inhibitor</td><td align="center">Targeted JAK</td><td align="center">Indication</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">BMS-911543</td><td align="center">JAK2</td><td align="center">Myelofibrosis             </td></tr><tr><td align="left"> AC-430</td><td align="center">JAK2</td><td align="center">Rheumatoid arthritis, lymphoma          </td></tr><tr><td align="left">CEP-33779</td><td align="center">JAK2</td><td align="center">Rheumatoid arthritis</td></tr><tr><td align="left">R723</td><td align="center">JAK2</td><td align="center">Myeloproliferative neoplasias                   </td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Selected JAK inhibitors in preclinical stage.

BioMed Research International

tab4

Table 4

Table 4: Role of STAT3 in Cancer Metastasis and Translational Advances 